The Effect of Diabetes on Pathologic Complete Response Among Patients With Esophageal Cancer

Diabetes is a common comorbidity in the U.S. and is associated with adverse outcomes in a variety of disease processes. Other cancer specialties have shown an association of diabetes with poor oncologic outcomes. We hypothesized that pathologic complete response (pCR) would be less likely among diab...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in thoracic and cardiovascular surgery 2023-01, Vol.35 (2), p.429-436
Main Authors: Alvarado, Christine E., Kapcio, Kevin C., Lada, Michal J., Linden, Philip A., Towe, Christopher W., Worrell, Stephanie G.
Format: Article
Language:English
Subjects:
Carcinoma, Squamous Cell - pathology
Diabetes
Diabetes Mellitus
Esophageal cancer
Esophageal Neoplasms
Esophagectomy - adverse effects
Esophagectomy - methods
Humans
Neoadjuvant Therapy - adverse effects
Neoadjuvant treatment
Neoplasm Staging
Pathologic complete response
Retrospective Studies
Survival Rate
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetes is a common comorbidity in the U.S. and is associated with adverse outcomes in a variety of disease processes. Other cancer specialties have shown an association of diabetes with poor oncologic outcomes. We hypothesized that pathologic complete response (pCR) would be less likely among diabetic patients with esophageal cancer who underwent neoadjuvant chemoradiation therapy followed by esophagectomy resulting in worse overall survival (OS). We performed a retrospective chart review at 2 high-volume academic hospitals of all patients with esophageal cancer who received neoadjuvant chemoradiation therapy followed by esophagectomy from 2010–2019. Patients were excluded if they had histology other than squamous cell carcinoma or adenocarcinoma, did not receive multi-agent chemotherapy or received a radiation dose
ISSN:1043-0679
1532-9488
DOI:10.1053/j.semtcvs.2021.10.016